Business Context and Reporting Period
Company: The Cooper Companies, Inc. (TCC)
Filing Type: Form 10-K (Annual Report)
Period Ended: October 31, 1996
Business Overview: TCC operates through three primary subsidiaries: CooperVision (contact lenses), CooperSurgical (diagnostic and surgical instruments), and Hospital Group of America (HGA) (psychiatric facilities). The company develops, manufactures, and markets healthcare products and provides healthcare services.
Key Financial Metrics
Note: Consolidated revenue, profit, and cash flow figures for the parent company are incorporated by reference to the Annual Report to Stockholders (Exhibit 13) and are not explicitly detailed in the provided text. The following metrics are derived from the standalone financial statements of subsidiaries included in the filing.
Hospital Group of America, Inc. (HGA)
| Metric | Fiscal 1996 | Fiscal 1995 |
|---|---|---|
| Net Operating Revenue | $43,013,000 | $40,912,000 |
| Net Loss | $(4,717,000) | $(11,078,000) |
| Total Assets | $50,515,000 | $50,400,000 |
| Long-Term Debt | $10,008,000 | $9,222,000 |
| Cash and Equivalents | $1,464,000 | $2,314,000 |
CooperSurgical, Inc. (CSI)
| Metric | Fiscal 1996 | Fiscal 1995 |
|---|---|---|
| Net Sales | $17,227,000 | $12,824,000 |
| Gross Profit | $8,758,000 | $6,642,000 |
| Net Loss | $(486,000) | $(1,390,000) |
| Total Assets | $10,622,000 | $9,150,000 |
| Long-Term Debt | $102,000 | $153,000 |
Research and Development (Consolidated)
Total R&D expenditures for the fiscal year ended October 31, 1996, were $1,176,000, a significant decrease from $2,914,000 in 1995. This reduction followed the decision to discontinue the development and outlicensing of a calcium channel blocker compound.
Material Changes and Operational Highlights
- CooperVision: Launched two major line extensions to the "Preference Toric" product line, creating the broadest product line in toric planned replacement lenses. International sales growth is being pursued through alliances in Latin America, the Middle East, and the Pacific Rim.
- CooperSurgical: Acquired Unimar, Inc. in April 1996, a provider of specialized disposable medical devices for gynecology. Net sales increased 34% year-over-year to $17.2 million. The segment also introduced the RUMI uterine manipulator system (FDA approved) and the KOH Colpotomizer System.
- Hospital Group of America: Net loss improved significantly from $11.1 million in 1995 to $4.7 million in 1996. This improvement was partially due to a one-time charge of $5.55 million in 1995 related to the settlement of a dispute with a medical group at Hampton Hospital. HGA increased ambulatory programs and acquired land in Kouts, Indiana, for a new 50-bed residential treatment center expected to open in mid-1997.
- Debt Refinancing: HGA renegotiated its bank term loan in September 1996, reducing the interest rate to 2% above prime (minimum 9%) and extending maturity to August 2001.
Guidance, Risks, and Contingencies
- Forward-Looking Statements: Management warns that actual results could differ materially from projections due to economic conditions, competitive inroads, regulatory delays, and changes in reimbursement rates.
- Reimbursement Risks: HGA faces significant risk from changes in government reimbursement programs (Medicare, Medicaid, CHAMPUS) and pressure from private payors/managed care organizations to reduce fees and limit services. Approximately 53% of HGA's net patient revenue in 1996 came from Medicaid and Medicare.
- Legal Proceedings:
- Historical Fraud: The Company was previously found guilty of mail and wire fraud regarding a "trading scheme" in 1994. Restitution and fines were paid or scheduled for payment through 1997. These amounts were charged against net income in prior years.
- Derivative Actions: The Company is a nominal defendant in stockholder derivative actions regarding the 1994 fraud. Settlement discussions are ongoing, but no assurance exists that litigation will end.
- HGA Disputes: HGA settled a dispute with Hampton Medical Group in December 1995, resulting in a $5.55 million charge in 1995. HGA continues to respond to inquiries from government agencies regarding billing practices at Hampton Hospital.
- Dividends: The Company does not anticipate paying cash dividends on common stock in the foreseeable future due to indenture restrictions requiring a Cash Flow Coverage Ratio of at least 1.5 to 1.
Investor Verification Checklist
- Consolidated Financials: Verify the consolidated revenue, net income, and cash flow figures in the Annual Report to Stockholders (Exhibit 13), as they are not explicitly listed in the 10-K text provided.
- Reimbursement Trends: Monitor changes in Medicare/Medicaid reimbursement rates and managed care contract terms, as these directly impact HGA's profitability.
- Legal Settlements: Track the status of the stockholder derivative litigation and any potential additional liabilities arising from the 1994 fraud case or HGA billing inquiries.
- Acquisition Integration: Assess the financial performance of the newly acquired Unimar, Inc. assets within CooperSurgical and the progress of the new HGA facility in Kouts, Indiana.
- Debt Covenants: Review the company's ability to maintain the required Cash Flow Coverage Ratio to avoid restrictions on restricted payments and ensure compliance with debt indentures.